We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
Analysts on Wall Street project that Amgen (AMGN - Free Report) will announce quarterly earnings of $5.00 per share in its forthcoming report, representing a decline of 10.4% year over year. Revenues are projected to reach $8.94 billion, increasing 5.2% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Amgen metrics that are routinely monitored and predicted by Wall Street analysts.
The average prediction of analysts places 'Revenue- Other revenues' at $373.34 million. The estimate suggests a change of +6.1% year over year.
Based on the collective assessment of analysts, 'Revenue- Product sales' should arrive at $8.55 billion. The estimate indicates a change of +4.8% from the prior-year quarter.
The consensus estimate for 'Product Sales- BLINCYTO- Total' stands at $412.70 million. The estimate points to a change of +26.2% from the year-ago quarter.
Analysts' assessment points toward 'Product Sales- Otezla- Total' reaching $582.08 million. The estimate suggests a change of +3.2% year over year.
The consensus among analysts is that 'Product Sales- Neulasta- U.S.' will reach $60.90 million. The estimate suggests a change of -27.5% year over year.
Analysts forecast 'Product Sales- Neulasta- ROW' to reach $19.55 million. The estimate points to a change of -24.8% from the year-ago quarter.
The combined assessment of analysts suggests that 'Product Sales- Repatha- U.S.' will likely reach $367.86 million. The estimate indicates a change of +30.9% from the prior-year quarter.
Analysts expect 'Product Sales- Repatha- ROW' to come in at $349.73 million. The estimate indicates a year-over-year change of +22.3%.
According to the collective judgment of analysts, 'Product Sales- KYPROLIS- ROW' should come in at $136.24 million. The estimate indicates a change of -2.7% from the prior-year quarter.
Analysts predict that the 'Product Sales- BLINCYTO- U.S.' will reach $298.45 million. The estimate indicates a change of +25.9% from the prior-year quarter.
It is projected by analysts that the 'Product Sales- BLINCYTO- ROW' will reach $117.64 million. The estimate suggests a change of +30.7% year over year.
The collective assessment of analysts points to an estimated 'Product Sales- KYPROLIS- U.S.' of $234.26 million. The estimate suggests a change of -1.6% year over year.
Shares of Amgen have demonstrated returns of -2.3% over the past month compared to the Zacks S&P 500 composite's +3.6% change. With a Zacks Rank #3 (Hold), AMGN is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Analysts on Wall Street project that Amgen (AMGN - Free Report) will announce quarterly earnings of $5.00 per share in its forthcoming report, representing a decline of 10.4% year over year. Revenues are projected to reach $8.94 billion, increasing 5.2% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Amgen metrics that are routinely monitored and predicted by Wall Street analysts.
The average prediction of analysts places 'Revenue- Other revenues' at $373.34 million. The estimate suggests a change of +6.1% year over year.
Based on the collective assessment of analysts, 'Revenue- Product sales' should arrive at $8.55 billion. The estimate indicates a change of +4.8% from the prior-year quarter.
The consensus estimate for 'Product Sales- BLINCYTO- Total' stands at $412.70 million. The estimate points to a change of +26.2% from the year-ago quarter.
Analysts' assessment points toward 'Product Sales- Otezla- Total' reaching $582.08 million. The estimate suggests a change of +3.2% year over year.
The consensus among analysts is that 'Product Sales- Neulasta- U.S.' will reach $60.90 million. The estimate suggests a change of -27.5% year over year.
Analysts forecast 'Product Sales- Neulasta- ROW' to reach $19.55 million. The estimate points to a change of -24.8% from the year-ago quarter.
The combined assessment of analysts suggests that 'Product Sales- Repatha- U.S.' will likely reach $367.86 million. The estimate indicates a change of +30.9% from the prior-year quarter.
Analysts expect 'Product Sales- Repatha- ROW' to come in at $349.73 million. The estimate indicates a year-over-year change of +22.3%.
According to the collective judgment of analysts, 'Product Sales- KYPROLIS- ROW' should come in at $136.24 million. The estimate indicates a change of -2.7% from the prior-year quarter.
Analysts predict that the 'Product Sales- BLINCYTO- U.S.' will reach $298.45 million. The estimate indicates a change of +25.9% from the prior-year quarter.
It is projected by analysts that the 'Product Sales- BLINCYTO- ROW' will reach $117.64 million. The estimate suggests a change of +30.7% year over year.
The collective assessment of analysts points to an estimated 'Product Sales- KYPROLIS- U.S.' of $234.26 million. The estimate suggests a change of -1.6% year over year.
View all Key Company Metrics for Amgen here>>>Shares of Amgen have demonstrated returns of -2.3% over the past month compared to the Zacks S&P 500 composite's +3.6% change. With a Zacks Rank #3 (Hold), AMGN is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .